Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedOral IL-23 receptor antagonist peptideFDA-approved March 2026 (Icotyde)Plaque psoriasis

Icotrokinra

A daily tablet that blocks the IL-23 receptor, the pathway injected biologics target in psoriasis

Icotrokinra is a 13-amino-acid oral peptide from Johnson & Johnson and Protagonist Therapeutics that blocks the interleukin-23 receptor, a driver of psoriasis inflammation. In two phase 3 trials, 68% to 70% of people reached clear or almost clear skin at week 16. Approved March 17, 2026.

Manufacturer's recommended dosing (FDA label): 200 mg, Once daily, on waking, 30 minutes before food, Oral Details ↓

Overview

What is it?

Interleukin-23 drives much of psoriasis inflammation, and the most effective treatments are injected antibodies against it. Icotrokinra blocks the IL-23 receptor instead, with a small engineered peptide. In human cells it inhibited IL-23 signalling at picomolar concentrations without affecting IL-12.

Being swallowed is its distinction and its constraint. In animals only 0.1% to 0.3% of an oral dose was absorbed, without any absorption enhancer, yet that was enough to act; the peptide survived gut fluids and reached the skin. The label's rule follows: 200 mg on waking with water, then 30 minutes before food, because a high-fat meal cut exposure by 43%.

In the phase 2b FRONTIER-1 trial, PASI 75 responses at 16 weeks rose with dose, to 79% at the highest dose against 9% on placebo, and in its extension 76% still had that response at a year. The phase 3 ICONIC-ADVANCE trials enrolled 1,505 adults and compared it with placebo and deucravacitinib. Clear or almost clear skin at week 16 was reached by 68% and 70% on icotrokinra, against 11% and 9% on placebo, and most responses held through a year.

The wider programme filled in the gaps. ICONIC-LEAD, which included adolescents, found 65% clear or almost clear against 8%, with adverse events equally common on drug and placebo. ICONIC-TOTAL looked at the hard-to-treat sites: scalp and genital psoriasis responded well, hands and feet less clearly. Against the injected antibodies there is no head-to-head trial; an indirect comparison co-authored by risankizumab's maker put that antibody ahead.

FDA approved it as Icotyde on March 17, 2026, for moderate-to-severe plaque psoriasis in adults and children 12 and older weighing at least 40 kg. The label warns about infections, though serious infections were 0.2% against 0.4% on placebo over 16 weeks, advises considering tuberculosis testing and avoiding live vaccines, and lists no contraindications. The EU authorised it on September 18, 2026.

Ulcerative colitis is the next test. In the phase 2b ANTHEM-UC trial, published in the New England Journal of Medicine in October 2026, 252 adults with moderately to severely active disease took 100, 200 or 400 mg once daily or placebo: clinical response at week 12 reached 55% to 63% on the three doses against 27% on placebo, and clinical remission 30% against 11% at the top dose. It is not approved for ulcerative colitis; the label covers plaque psoriasis.

68-70%
Clear or almost clear skin at week 16
9-11% on placebo (ICONIC-ADVANCE) · PMID 40976249
200 mg
One tablet on waking
30 minutes before food · PMID 42874103
7 pM
Binding to the IL-23 receptor
Icotyde label
Science

Mechanism of Action

Icotrokinra is a peptide that binds the IL-23 receptor with a dissociation constant of 7 pM and stops IL-23 from signalling through it (label).

🎯

IL-23 receptor blocked

Binds IL-23R selectively and antagonises IL-23 binding (label); it did not affect IL-12 signalling in human cells.

🧯

Less inflammatory signalling

Blocking the receptor inhibits the IL-23-dependent release of proinflammatory cytokines that sustain psoriasis plaques (label).

💊

An oral peptide

Peak levels about 2 hours after the dose, steady state in about 3 days, half-life about 12 hours; broken down into smaller peptides (label).

Evidence

Published Research

The trials behind icotrokinra, from PubMed abstracts.

Human2025

ICONIC-ADVANCE 1 and 2: 1,505 adults

Clear or almost clear skin (IGA 0 or 1) at week 16 was reached by 68% and 70% on icotrokinra against 11% and 9% on placebo; PASI 90 by 55% against 4% in the first trial.

PMID: 40976249
Human2026

One-year durability

Among those randomised to icotrokinra, about 70% to 75% had clear or almost clear skin and about 50% completely clear skin during weeks 24 to 52; 85% to 90% of week-16 responders maintained their response at week 52.

PMID: 42397072
Human2026

Safety through one year

Across 1,840 participant-years, adverse events, serious adverse events, infections and discontinuations through week 16 were comparable to placebo.

PMID: 42663861
Human2025

ICONIC-LEAD: adults and adolescents

In 684 participants aged 12 and over, 65% on icotrokinra against 8% on placebo had clear or almost clear skin at week 16, and 27% against under 1% were completely clear (PASI 100); adverse events occurred in 49% of both groups.

PMID: 41191940
Human2025

ICONIC-TOTAL: scalp, genital, hands and feet

In 311 participants with psoriasis at high-impact sites, clear or almost clear skin at week 16 was reached by 56.7% against 5.8%; scalp and genital responses were significantly better, while hand and foot (41.7% against 26.1%) did not reach significance.

PMID: 41191932
Human2025

FRONTIER-2: the phase 2b to one year

Of FRONTIER-1 patients, 89% continued; on the highest dose (100 mg twice daily), 76% had PASI 75 and 40% PASI 100 at week 52; serious adverse events, judged unrelated, occurred in 4%.

PMID: 39549848
Human2026

Indirect comparison with risankizumab

A matching-adjusted indirect comparison, with AbbVie (risankizumab's maker) among the authors, found injected risankizumab ahead at week 16 (PASI 90 71.4% against 49.9%; IGA 0/1 77.8% against 58.4%), with consistent results through week 52.

PMID: 42393457
Human2026

Ulcerative colitis: ANTHEM-UC, 252 adults

In a phase 2b double-blind trial in adults with moderately to severely active ulcerative colitis, clinical response at week 12 was reached by 63%, 58% and 55% on 400, 200 and 100 mg once daily against 27% on placebo; clinical remission on 400 mg was 30% against 11%, and serious adverse events through week 28 occurred in 2%, 5% and 0% against 10% on placebo.

PMID: 42874103
Human2025

What it does in blood and skin

In FRONTIER-1 and its extension, icotrokinra lowered serum markers of the IL-23/IL-17 pathway in a dose-dependent way from week 4 through week 52 without broader changes in circulating proteins, and after 16 weeks it reduced psoriasis-related gene expression in lesional skin; the reductions tracked clinical response.

PMID: 41424381
Human2026

Hard-to-treat sites at one year

In ICONIC-TOTAL (311 people aged 12 and over with scalp, genital or hand and foot psoriasis), responses on 200 mg once daily held from week 24 to week 52: clear or almost clear scalp in 72-78%, genital skin in 85-90% and hands and feet in 54-62%, while nail improvement rose from 33% at week 16 to 62%, with no new safety signal.

PMID: 42175814
In Vitro2024

How potent and selective it is

It bound the IL-23 receptor with a dissociation constant of 7.1 pM and blocked IL-23 signalling in human cells (IC50 5.6 pM) without affecting IL-12 signalling.

PMID: 39080319
Animal2025

How an oral peptide gets in

In rats and monkeys, oral bioavailability was 0.1% to 0.3% without an absorption enhancer, yet enough for systemic activity; the peptide was stable in gut fluids, reached skin and joints, and was mostly excreted unabsorbed in faeces.

PMID: 40629250
Review2026

Pooled: five trials, 1,951 people

A meta-analysis with trial sequential analysis of five randomised trials (1,951 participants) found PASI 75 at week 16 in 73% on 200 mg once daily against 11% on placebo and PASI 100 in 30% against 1%, with no significant difference in adverse events, serious adverse events or infections.

PMID: 41846234
Dosing

Dosing Data

Icotyde is one 200 mg tablet a day, taken on waking on an empty stomach with water, at least 30 minutes before food; it can be dispersed in water for people who cannot swallow tablets.

Prescription only. Consider tuberculosis testing first, complete vaccinations, and avoid live vaccines during treatment.
ProtocolDoseFrequencyDurationRoute
Label: moderate-to-severe plaque psoriasis, adults and children 12+ weighing at least 40 kg Approved labelICOTYDE (icotrokinra) tablets Prescribing Information, sections 1, 2, 5, 6 and 12 (DailyMed version 2, effective March 17, 2026)200 mgOnce daily, on waking, 30 minutes before foodOngoingOral

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

→ Full Icotrokinra dosage guide — the Icotyde label's fixed dose

Fixed dose
Icotrokinra is one 200 mg tablet a day; there is nothing to calculate.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Icotyde (icotrokinra tablet): Tablets: 200 mg. Forms the label lists: tablets.

Source: Icotyde (icotrokinra tablet) label, section 3 (DailyMed version 2, effective March 17, 2026).

Mixing a vial: a worked example

Nothing to mix: the label gives Icotyde (icotrokinra tablet) as tablets, ready to use.

Source: Icotyde (icotrokinra tablet) label, sections 2, 3 and 16 (DailyMed version 2, effective March 17, 2026).

Storage before and after mixing

Before mixing or first use: “Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F).” “Store in original package to protect from moisture.” “Do not discard desiccant.”

After mixing or first use: the label sentences we read say nothing separate about this.

Source: Icotyde (icotrokinra tablet) label, sections 16 and 2 (DailyMed version 2, effective March 17, 2026).

How it is taken

As the approved label gives it: Oral (Once daily, on waking, 30 minutes before food; Label: moderate-to-severe plaque psoriasis, adults and children 12+ weighing at least 40 kg).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of about 12 hours. After about five half-lives almost none is left.

When effects appear: unknown; no source on this page gives a time to effect for Icotrokinra. Results reported in the studies are under Published Research.

Source: half-life: Icotyde prescribing information, section 12.3 (DailyMed version 2, effective March 17, 2026; read September 30, 2026).

Side effects, and when to stop or get help

From the Side Effects section: Infections — the label advises against starting it during an important active infection; Adverse event rates comparable to placebo through week 16 in the pooled trials; No contraindications listed on the label. Full list and cautions ↓

When the label says to stop or get help:

  • Infections: Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated. If such an infection develops, discontinue ICOTYDE until the infection resolves.

Source: Icotyde (icotrokinra tablet) label, boxed warning and section 5 (DailyMed version 2, effective March 17, 2026); the Side Effects section below (“From the Icotyde label and the trials above”).

Interactions

Unknown: a PubMed search for human interaction studies of Icotrokinra (reviewed 2026-09-30) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Icotrokinra products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Icotrokinra's expected mass, 1,898.2 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved. Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the Icotyde label and the trials above.

● Infections — the label advises against starting it during an important active infection
● Adverse event rates comparable to placebo through week 16 in the pooled trials
● No contraindications listed on the label

Contraindications & Cautions

From the label; a clinician decides.

● Active, clinically important infection — treat it first
● Tuberculosis — consider testing before starting
● Live vaccines — avoid during treatment
Questions

Frequently Asked Questions

?What is icotrokinra?

A daily tablet, sold as Icotyde, containing a 13-amino-acid peptide that blocks the IL-23 receptor, a key driver of psoriasis inflammation.

?How well does it work?

In two phase 3 trials, 68% and 70% of people had clear or almost clear skin at week 16, against 11% and 9% on placebo, and most responses lasted through a year.

?How do you take it?

200 mg once a day on waking, with water, on an empty stomach, waiting at least 30 minutes before eating; the tablet can be dispersed in water.

?Is it as good as the injected IL-23 drugs?

No head-to-head trial exists. An indirect comparison co-authored by AbbVie, which makes risankizumab, found that injected antibody gave higher response rates at week 16 and through a year. In its own phase 3 trials icotrokinra beat both placebo and deucravacitinib, another oral psoriasis drug.

?Can teenagers take it?

Yes, from age 12 if they weigh at least 40 kg. The ICONIC-LEAD trial included adolescents, and 65% of all participants on icotrokinra had clear or almost clear skin at week 16 against 8% on placebo. For anyone who struggles with tablets, the label allows dispersing it in water.

?Has it been tested in ulcerative colitis?

In one phase 2b trial so far. In ANTHEM-UC (New England Journal of Medicine, 2026), 252 adults with moderately to severely active ulcerative colitis took 100, 200 or 400 mg once daily or placebo; at week 12, clinical response was 55%, 58% and 63% on the three doses against 27% on placebo. Ulcerative colitis is not an approved use.

?Can it be taken while breastfeeding?

There are no data. LactMed, the NIH's lactation database, reasons that its size (1,898 daltons) and digestion in the infant's gut make meaningful exposure unlikely and that needing it is not a reason to stop breastfeeding, but advises caution until data exist, especially with a newborn or preterm infant. That is a decision to make with the prescriber.

Bibliography

References

  1. [fda-pi] Janssen Biotech. ICOTYDE (icotrokinra) tablets, US prescribing information: indication, dosage (200 mg once daily on waking), warnings (infections, tuberculosis, live vaccines), no contraindications, mechanism (IL-23R, KD 7 pM) and pharmacokinetics (half-life about 12 hours). DailyMed set aee3c963, version 2, effective March 17, 2026; read September 30, 2026.
  2. [pubmed] Gold LS, et al. "Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials." Lancet, 2025;406(10510):1363-1374. PMID: 40976249.
  3. [pubmed] Stein Gold L, et al. "Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials." Br J Dermatol, 2026;195(4):600. PMID: 42397072.
  4. [pubmed] Lebwohl MG, et al. "Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials." Dermatol Ther (Heidelb), 2026. PMID: 42663861.
  5. [pubmed] Fourie AM, et al. "JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans." Sci Rep, 2024;14(1):17515. PMID: 39080319.
  6. [pubmed] Bissonnette R, et al. "An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis." N Engl J Med, 2024;390(6):510-521. PMID: 38324484.
  7. [fda] FDA. Drugs@FDA (openFDA): ICOTYDE NDA 220149, approved March 17, 2026; and FDA, Novel Drug Approvals for 2026 (content current as of September 28, 2026). Read September 30, 2026.
  8. [other] European Medicines Agency. Medicines register: Icotyde, authorised September 18, 2026. Read September 30, 2026.
  9. [pubmed] Bissonnette R, et al. "Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents." N Engl J Med, 2025;393(18):1784-1795. PMID: 41191940.
  10. [pubmed] Gooderham M, et al. "Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites." NEJM Evid, 2025;4(12):EVIDoa2500155. PMID: 41191932.
  11. [pubmed] Ferris LK, et al. "FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis." J Am Acad Dermatol, 2025;92(3):495-502. PMID: 39549848.
  12. [pubmed] Crowley J, et al. "Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis." Dermatol Ther (Heidelb), 2026;16(8):4139-4153. PMID: 42393457.
  13. [pubmed] Knight B, et al. "Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling." Dermatol Ther (Heidelb), 2025;15(9):2495-2520. PMID: 40629250.
  14. [pubmed] Abreu MT, et al. "Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis." N Engl J Med, 2026;395(15):1495-1504. PMID: 42874103.
  15. [pubmed] Strawn D, et al. "Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis." JCI Insight, 2025;10(24). PMID: 41424381.
  16. [pubmed] Warren RB, et al. "Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings." J Eur Acad Dermatol Venereol, 2026;40(9):1502-1514. PMID: 42175814.
  17. [pubmed] Altayf A, et al. "Efficacy and Safety of Oral Icotrokinra in Moderate-to-Severe Plaque Psoriasis: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis." Int J Dermatol, 2026;65(6):1144-1154. PMID: 41846234.
  18. [pubmed] Soung J, et al. "Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study." J Am Acad Dermatol, 2026;95(4):1109-1112. PMID: 42176706.
  19. [pubmed] Soung J, et al. "Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial." J Am Acad Dermatol, 2026;95(4):1103-1106. PMID: 42144198.
  20. [pubmed] Millette D. "Durability of response to icotrokinra in the ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials: a potential new novel oral treatment for psoriasis." Br J Dermatol, 2026;195(4):564-565. PMID: 42563545.
  21. [pubmed] Gupta S, et al. "The efficacy of oral icotrokinra versus injectable IL-23 inhibitors for moderate-to-severe plaque psoriasis: A comparative meta-analysis." J Am Acad Dermatol, 2026. PMID: 42570846.
  22. [pubmed] Keam SJ. "Icotrokinra: First Approval." Drugs, 2026;86(8):1401-1407. PMID: 42243571.
  23. [pubmed] "Icotrokinra." , 2006. PMID: 42044247.
  24. [pubmed] Puig L. "Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy." Lancet, 2025;406(10510):1316-1318. PMID: 40976247.
  25. [pubmed] Habib E, et al. "Oral icotrokinra for plaque psoriasis in adults and adolescents." Ann Med Surg (Lond), 2026;88(1):1064-1065. PMID: 41497080.
  26. [pubmed] Abid MA, et al. "FDA approves Icotyde(TM) (Icotrokinra): a novel IL-23 receptor antagonist for plaque psoriasis." Ann Med Surg (Lond), 2026;88(7):4769-4770. PMID: 42433845.
  27. [pubmed] "Icotrokinra (Icotyde) for psoriasis." Med Lett Drugs Ther, 2026;68(1760):122-124. PMID: 42497846.
  28. [pubmed] Noviello D, et al. "Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra." Expert Opin Emerg Drugs, 2026:1-4. PMID: 42779386.
  29. [pubmed] Ferreira C, et al. "Icotrokinra: An Oral Interleukin-23 Receptor Antagonist Peptide for the Treatment of Psoriasis." Am J Clin Dermatol, 2026;27(3):479-492. PMID: 41817926.
  30. [pubmed] Okundia F, et al. "Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis." Skin Therapy Lett, 2026;31(1):4-7. PMID: 41557953.
  31. [pubmed] Siddiqi ZA, et al. "Efficacy and Safety of Icotrokinra (an Interleukin-23 Inhibitor) in the Management of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis." JMA J, 2026;9(5):1397-1405. PMID: 42840331.
  32. [pubmed] Advani S, et al. "Efficacy and Safety of Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-analysis." Clin Exp Dermatol, 2026. PMID: 42308521.
  33. [pubmed] AlJuma RS, et al. "Safety and efficacy of oral icotrokinra for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials." Front Immunol, 2026;17:1768292. PMID: 41869308.
  34. [pubmed] Cevallos-Cueva M, et al. "A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials." Inflammopharmacology, 2026;34(6):3783-3795. PMID: 41774413.
  35. [pubmed] Abdeldayem MR, et al. "Safety and Efficacy of the Oral IL-23 Receptor Antagonist Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." J Cutan Med Surg, 2026:12034754261419058. PMID: 41679329.

Sources & Citations

Studies were read from their PubMed abstracts; the Icotyde label (DailyMed version 2, effective March 17, 2026) was read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-16